NCT04685993View on ClinicalTrials.gov

A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 11, 2020

Primary Completion Date

March 1, 2022

Study Completion Date

March 1, 2022

Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
DRUG

LPCN 1144

Oral LPCN 1144, total daily dose of 450 mg testosterone undecanoate administered as BID (225 mg testosterone undecanoate per dose).

Trial Locations (10)

20110

Manassas Clinical Research Center, Manassas

34761

Sensible Healthcare, LLC, Ocoee

77479

Pioneer Research Soultions, Sugar Land

77494

R&H Clinical Research, Katy

78215

Sun Research Institute, San Antonio

78229

Endeavor Clinical Trials, San Antonio

84065

Advanced Clinical Research - Gut Whisperer, Riverton

84120

Granger Medical Clinic, West Valley City

89106

Jubilee Clinical Research, Inc., Las Vegas

95661

Clinical Trials Research, Roseville

Sponsors

Lead Sponsor

Lipocine Inc.
All Listed Sponsors
lead

Lipocine Inc.

INDUSTRY

NCT04685993 - A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial | Biotech Hunter | Biotech Hunter